{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:16:45Z","timestamp":1792815405073,"version":"4.5.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"crossref","award":["20163828"],"award-info":[{"award-number":["20163828"]}],"id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jean and Stephan Kaplan"},{"name":"Aramont Clinical\/Translational Research Program in Hematologic Malignancies"},{"name":"Hornsey Foundation"},{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"crossref","award":["R35CA197633"],"award-info":[{"award-number":["R35CA197633"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"crossref","award":["P30CA016042"],"award-info":[{"award-number":["P30CA016042"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jaime Erin Follicular Lymphoma Research Consortium"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>To address antigen escape and loss of T-cell functionality, we report a phase I clinical trial (NCT04007029) evaluating autologous naive and memory T (TN\/MEM) cells engineered to express a bispecific anti-CD19\/CD20 chimeric antigen receptor (CAR; CART19\/20) for patients with relapsed\/refractory non-Hodgkin lymphoma (NHL), with safety as the primary endpoint. Ten patients were treated with 36 \u00d7 106 to 165 \u00d7 106 CART19\/20 cells. No patient experienced neurotoxicity of any grade or over grade 1 cytokine release syndrome. One case of dose-limiting toxicity (persistent cytopenia) was observed. Nine of 10 patients achieved objective response [90% overall response rate (ORR)], with seven achieving complete remission [70% complete responses (CR) rate]. One patient relapsed after 18 months in CR but returned to CR after receiving a second dose of CART19\/20 cells. Median progression-free survival was 18 months and median overall survival was not reached with a 17-month median follow-up. In conclusion, CART19\/20 TN\/MEM cells are safe and effective in patients with relapsed\/refractory NHL, with durable responses achieved at low dosage levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Autologous CD19\/CD20 bispecific CAR-T cell therapy generated from TN\/MEM cells for patients with NHL is safe (no neurotoxicity, maximum grade 1 cytokine release syndrome) and demonstrates strong efficacy (90% ORR, 70% CR rate) in a first-in-human, phase I dose-escalation trial.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 517<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-22-0964","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T14:06:54Z","timestamp":1669212414000},"page":"580-597","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["CD19\/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive\/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma"],"prefix":"10.1158","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-2925","authenticated-orcid":false,"given":"Sarah M.","family":"Larson","sequence":"first","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."},{"name":"2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-7870","authenticated-orcid":false,"given":"Christopher M.","family":"Walthers","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9357-1616","authenticated-orcid":false,"given":"Brenda","family":"Ji","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1610-220X","authenticated-orcid":false,"given":"Sanaz N.","family":"Ghafouri","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2047-4532","authenticated-orcid":false,"given":"Jacob","family":"Naparstek","sequence":"additional","affiliation":[{"name":"4Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3726-4646","authenticated-orcid":false,"given":"Jacqueline","family":"Trent","sequence":"additional","affiliation":[{"name":"4Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3992-9143","authenticated-orcid":false,"given":"Jia Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"4Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7073-6617","authenticated-orcid":false,"given":"Mobina","family":"Roshandell","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2325-1729","authenticated-orcid":false,"given":"Caitlin","family":"Harris","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6734-7741","authenticated-orcid":false,"given":"Mobina","family":"Khericha","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4541-8403","authenticated-orcid":false,"given":"Thomas","family":"Schweppe","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5972-9029","authenticated-orcid":false,"given":"Beata","family":"Berent-Maoz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."},{"name":"4Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3840-8226","authenticated-orcid":false,"given":"Stanley B.","family":"Gosliner","sequence":"additional","affiliation":[{"name":"5Department of Chemical and Biomolecular Engineering, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-6818","authenticated-orcid":false,"given":"Amr","family":"Almaktari","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2906-5786","authenticated-orcid":false,"given":"Melanie Ayala","family":"Ceja","sequence":"additional","affiliation":[{"name":"3Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3525-3695","authenticated-orcid":false,"given":"Martin S.","family":"Allen-Auerbach","sequence":"additional","affiliation":[{"name":"6Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9474-2563","authenticated-orcid":false,"given":"Jonathan","family":"Said","sequence":"additional","affiliation":[{"name":"7Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6400-2449","authenticated-orcid":false,"given":"Karla","family":"Nawaly","sequence":"additional","affiliation":[{"name":"4Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9175-0189","authenticated-orcid":false,"given":"Monica","family":"Mead","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-4851","authenticated-orcid":false,"given":"Sven","family":"de Vos","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."},{"name":"2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-9377","authenticated-orcid":false,"given":"Patricia A.","family":"Young","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6368-8557","authenticated-orcid":false,"given":"Caspian","family":"Oliai","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7508-3467","authenticated-orcid":false,"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."},{"name":"2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4104-8943","authenticated-orcid":false,"given":"John M.","family":"Timmerman","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."},{"name":"2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, California."},{"name":"2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California."},{"name":"4Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, California."},{"name":"8Department of Surgery, Division of Surgical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California."},{"name":"9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5583-119X","authenticated-orcid":false,"given":"Yvonne Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California."},{"name":"3Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California."},{"name":"4Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, California."},{"name":"5Department of Chemical and Biomolecular Engineering, UCLA, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"2025121106385431700_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2025121106385431700_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2025121106385431700_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2025121106385431700_bib4","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"2025121106385431700_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121106385431700_bib6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2025121106385431700_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1158\/2326-6066.CIR-16-0108","article-title":"ADDENDUM: T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2025121106385431700_bib8","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"2025121106385431700_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2008.001024","article-title":"CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure","volume":"94","author":"Johnson","year":"2009","journal-title":"Haematologica"},{"key":"2025121106385431700_bib10","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"2025121106385431700_bib11","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"2025121106385431700_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"2025121106385431700_bib13","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Transduct Target Ther"},{"key":"2025121106385431700_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025121106385431700_bib15","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1172\/JCI136872","article-title":"Replacing CAR-T cell resistance with persistence by changing a single residue","volume":"130","author":"Hsieh","year":"2020","journal-title":"J Clin Invest"},{"key":"2025121106385431700_bib16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"2025121106385431700_bib17","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"2025121106385431700_bib18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"2025121106385431700_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Invest"},{"key":"2025121106385431700_bib20","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"2025121106385431700_bib21","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"key":"2025121106385431700_bib22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/mthe.2002.0558","article-title":"Design of HIV vectors for efficient gene delivery into human hematopoietic cells","volume":"5","author":"Yam","year":"2002","journal-title":"Mol Ther"},{"key":"2025121106385431700_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025121106385431700_bib24","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nrc2250","article-title":"Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy","volume":"7","author":"Colombo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2025121106385431700_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2018.10.004","article-title":"Manufacture of chimeric antigen receptor T cells from mobilized cyropreserved peripheral blood stem cell units depends on monocyte depletion","volume":"25","author":"Kunkele","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025121106385431700_bib26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"2025121106385431700_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"2025121106385431700_bib28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"key":"2025121106385431700_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"2025121106385431700_bib30","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"2025121106385431700_bib31","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"2025121106385431700_bib32","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"2025121106385431700_bib33","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"2025121106385431700_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1\u20132 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"2025121106385431700_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025121106385431700_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025121106385431700_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"2025121106385431700_bib38","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025121106385431700_bib39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2025121106385431700_bib40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"2025121106385431700_bib41","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am J Hematol"},{"key":"2025121106385431700_bib42","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood-2019-128068","article-title":"Upregulation of senescent\/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed\/refractory B cell malignancies","volume":"134","author":"Beider","year":"2019","journal-title":"Blood"},{"key":"2025121106385431700_bib43","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"2025121106385431700_bib44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"2025121106385431700_bib45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025121106385431700_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy: assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121106385431700_bib47","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025121106385431700_bib48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-22-0964\/3262903\/cd-22-0964.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-22-0964\/3268802\/cd-22-0964.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/13\/3\/580\/3277332\/580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/13\/3\/580\/3277332\/580.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:39:09Z","timestamp":1765453149000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/13\/3\/580\/716747\/CD19-CD20-Bispecific-Chimeric-Antigen-Receptor-CAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,11,23]]},"published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-22-0964","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22542525.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542531.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6549963.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542522.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542540.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542537.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542528.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542543","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542534.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542531","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542525","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542537","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542528","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6549963","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542543.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542540","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542534","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22542522","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2022.09.13.22279873","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.30858608","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30858620","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30858626","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30858614","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30858617","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30858605","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30858611","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.30858623","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]}}}